Kalvista Pharmaceuticals Inc (NASDAQ:KALV) was the target of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 877,600 shares, an increase of 11.3% from the December 15th total of 788,700 shares. Approximately 7.0% of the company’s shares are sold short. Based on an average daily trading volume, of 154,400 shares, the days-to-cover ratio is currently 5.7 days.

Several equities analysts have recently issued reports on KALV shares. Needham & Company LLC dropped their price target on shares of Kalvista Pharmaceuticals from $35.00 to $28.00 and set a “buy” rating for the company in a research note on Tuesday, December 10th. BidaskClub cut shares of Kalvista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, January 10th. Zacks Investment Research raised Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a research note on Friday, December 6th. Finally, ValuEngine raised shares of Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Kalvista Pharmaceuticals presently has an average rating of “Buy” and an average price target of $27.20.

In other news, CEO Thomas Andrew Crockett sold 5,400 shares of the firm’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $17.06, for a total transaction of $92,124.00. Following the completion of the transaction, the chief executive officer now owns 248,320 shares of the company’s stock, valued at $4,236,339.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Christopher Yea sold 3,010 shares of the firm’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $17.05, for a total transaction of $51,320.50. Following the transaction, the insider now directly owns 83,168 shares of the company’s stock, valued at approximately $1,418,014.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 10,010 shares of company stock valued at $170,720. 21.60% of the stock is owned by company insiders.

Hedge funds have recently made changes to their positions in the company. FMR LLC purchased a new stake in shares of Kalvista Pharmaceuticals during the 1st quarter valued at $21,036,000. BlackRock Inc. increased its holdings in Kalvista Pharmaceuticals by 948.7% in the 2nd quarter. BlackRock Inc. now owns 736,782 shares of the specialty pharmaceutical company’s stock worth $16,320,000 after acquiring an additional 666,525 shares during the last quarter. Pictet Asset Management Ltd. purchased a new stake in Kalvista Pharmaceuticals in the 2nd quarter worth about $10,067,000. Eventide Asset Management LLC increased its holdings in Kalvista Pharmaceuticals by 12.0% in the 3rd quarter. Eventide Asset Management LLC now owns 1,680,000 shares of the specialty pharmaceutical company’s stock worth $19,488,000 after acquiring an additional 180,000 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in Kalvista Pharmaceuticals by 47.7% in the 2nd quarter. Vanguard Group Inc. now owns 527,829 shares of the specialty pharmaceutical company’s stock worth $11,692,000 after acquiring an additional 170,439 shares during the last quarter. Institutional investors own 82.21% of the company’s stock.

KALV stock traded up $1.02 during mid-day trading on Thursday, reaching $18.00. 3,684 shares of the company traded hands, compared to its average volume of 113,194. The company has a quick ratio of 10.30, a current ratio of 10.31 and a debt-to-equity ratio of 0.01. The firm’s 50 day moving average price is $16.13 and its 200 day moving average price is $14.89. The stock has a market cap of $309.53 million, a price-to-earnings ratio of -12.93 and a beta of 2.22. Kalvista Pharmaceuticals has a fifty-two week low of $9.86 and a fifty-two week high of $34.92.

Kalvista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Tuesday, December 3rd. The specialty pharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.55) by $0.22. Kalvista Pharmaceuticals had a negative return on equity of 25.70% and a negative net margin of 182.37%. The company had revenue of $3.92 million for the quarter, compared to analysts’ expectations of $3.23 million. On average, analysts anticipate that Kalvista Pharmaceuticals will post -1.63 EPS for the current fiscal year.

Kalvista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Recommended Story: What is Liquidity?

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.